Other Solid Tumors Research Studies

< Back to Pediatric Cancer Research Studies Page

Solid Tumors Melanoma New Diagnosis

BRF116013: A Phase I/IIa, 2 Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Pediatric Patients Aged 1 Month to <18 years with Advanced BRAF V600-Mutation Positive Solid Tumors.

  • Conditions: Brain Spinal Tumors Medulloblastoma Relapse, Brain Spinal Tumor Low Grade Glioma Relapse, Brain Spinal Tumor DIPG Relapse, Brain and Spinal Tumor Ependymoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Brain Spinal Neurofibromatosis OPG, Brain Spinal Other ATRT, Brain Spinal Other Craniopharyngioma, Brain Spinal Other Germ Cell Tumor, Brain Spinal Other Choroid Plexus Tumor, Brain Spinal Other All Other, Sarcoma Ewing Relapse, Sarcoma Osteosarcoma Relapse, Sarcoma Rhabdomyosarcoma Relapse, Neuroblastoma Relapse - Refractory, Liver Relapse - Refractory, Kidney Relapse - Refractory, Solid Tumor Retinoblastoma Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory, Solid Tumor Neurofibromatosis OPG Low Grade Glioma, Solid Tumor Melanoma New Diagnosis, Solid Tumor Melanoma Relapse - Refractory, Solid Tumor Germ Cell Tumor Relapse - Refractory, Solid Tumors - All Other

PURPOSE:   This is a 2-part, study to determine the safety, tolerability and pharmacokinetics of oral dabrafenib in pediatric subjects with advanced BRAF V600 mutation-positive solid tumors. Part 1 (dose escalation study) will identify the recommended Part 2 (tumor-specific expansion study ...More